Research from University of Miami and Tetra Discovery Shows Potential of Novel Drug to Improve Memory after Traumatic Brain Injury

Treating rats with an experimental drug at three months following a traumatic brain injury (TBI) improves their learning memory ability, as reported in a new study published online today in the July edition of The Journal of Neuroscience. The drug, a selective phosphodiesterase 4 subtype inhibitor (PDE4B), is currently under development by Tetra Discovery Partners,…

Details

Tetra Discovery Advances Alzheimer’s Treatment Candidate BPN14770 to Phase I Multiple Ascending Dose Trial

Tetra Discovery Partners (“Tetra”) today announced that the company has successfully completed its initial Phase 1 single ascending dose (SAD) study of BPN14770 safety in 32 healthy volunteers. BPN14770 is the company’s experimental treatment aimed at improving memory and slowing the progression of Alzheimer’s disease. Tetra plans to begin its second Phase 1 trial of…

Details

Tetra Discovery Initiates Phase 1 Study of BPN14770, Under Development for Treatment and Prevention of Alzheimer’s Disease

Tetra Discovery Partners (“Tetra”) today announced that the company has initiated human Phase 1 safety trials of its lead compound BPN14770, which Tetra is developing as a potential treatment to both improve memory and slow the progression of Alzheimer’s disease. “There is a rapidly rising need for improved therapies for Alzheimer’s disease. BPN14770 offers a…

Details

Tetra Discovery Partners Announces Additional Financing and Formation of Scientific Advisory Board

Tetra Discovery Partners (“Tetra”), a drug discovery company developing a portfolio of innovative drugs for psychiatric, neurological and inflammatory diseases, today announced additional private financing. The company has received additional financing from previous seed investor Grand Angels, as well as an investment by Johnson & Johnson Development Corporation (JJDC). Tetra additionally announced the formation of…

Details

Tetra Discovery to Collaborate with The Broad Institute’s Stanley Center for Psychiatric Research To Pursue Schizophrenia Therapeutics

Tetra Discovery Partners LLC, a drug discovery company developing a portfolio of innovative drugs for neurological and inflammatory diseases, announced today that the company has entered into a drug development collaboration with the Broad Institute’s Stanley Center for Psychiatric Research in Cambridge, MA. The focus of the collaboration will be to test the potential of…

Details

Promising Life Science Start-up Continues Breaking Milestones with Business Assistance & Funding from a Collaboration of MI-based Programs

Leading inventor of Alzheimer’s disease treatments, Dr. Mark Gurney, continues to grow his West Michigan-based lean, biotech start-up – Tetra Discovery Partners, LLC (Tetra) – through the support of a collaboration of Michigan entrepreneurial and funding programs. Tetra is working on the development of three new drugs targeted at improving treatments for Alzheimer’s, depression, and…

Details